---
title: "Citi Keeps Their Buy Rating on Vertex Pharmaceuticals (VRTX)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/299884631.md"
description: "In a report released today, Geoff Meacham from Citi maintained a Buy rating on Vertex Pharmaceuticals, with a price target of $585.00. Meacham covers the Healthcare sector, focusing on stocks such as Amgen, Vertex Pharmaceuticals, and Biogen. According to TipRanks, Meacham has an average return of 16.2% and a 59.75% success rate on recommended stocks. In addition to Citi, Vertex Pharmaceuticals also received a Buy from Barclays’s Eliana Merle in a report issued today. However, yesterday, Stifel Nicolaus maintained a Hold rating on Vertex Pharmaceuticals (NASDAQ: VRTX)."
datetime: "2026-09-23T10:57:09.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/299884631.md)
  - [en](https://longbridge.com/en/news/299884631.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/299884631.md)
generator: "portal-rs"
---

# Citi Keeps Their Buy Rating on Vertex Pharmaceuticals (VRTX)

In a report released today, Geoff Meacham from Citi maintained a Buy rating on Vertex Pharmaceuticals, with a price target of $585.00.

Meacham covers the Healthcare sector, focusing on stocks such as Amgen, Vertex Pharmaceuticals, and Biogen. According to TipRanks, Meacham has an average return of 16.2% and a 59.75% success rate on recommended stocks. 

In addition to Citi, Vertex Pharmaceuticals also received a Buy from Barclays’s Eliana Merle in a report issued today. However, yesterday, Stifel Nicolaus maintained a Hold rating on Vertex Pharmaceuticals (NASDAQ: VRTX).

### Related Stocks

- [VRTX.US](https://longbridge.com/en/quote/VRTX.US.md)

## Related News & Research

- [Vertex Touts Encouraging Data From 'Underappreciated' Kidney Drug](https://longbridge.com/en/news/299800601.md)
- [Vertex Pharmaceuticals Incorporated Says Inaxaplin Reduces UACR By -42.7% At Week 13 In AMKD With Modest Proteinuria](https://longbridge.com/en/news/299770014.md)
- [Vertex says Phase 2b AMPLIFIED study shows inaxaplin cuts proteinuria in APOL1-mediated kidney disease patients with modest proteinuria](https://longbridge.com/en/news/299762830.md)
- [Meta vs. Microsoft: One Hyperscaler Stock Has Room to Grow, the Other Lacks a Catalyst, Says Investor](https://longbridge.com/en/news/300456248.md)
- [Bill Ackman Happy to be Back in Netflix Stock Again: ‘Amazing Business With a Very Dominant Position’](https://longbridge.com/en/news/300489914.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**